HLA-DRB1、DQB1多态性与直肠癌化疗前后血常规指标变化的关联
Association between Polymorphism of HLA-DRB1, DQB1 and changes of routine blood indexes from Rectal Cancer Chemotherapy
佟凤芝 1侯艺 1王娜 1刘辉2
作者信息
- 1. 116021 辽宁省大连市第五人民医院检验科
- 2. 116044 大连医科大学检验医学院
- 折叠
摘要
目的通过直肠癌患者在化疗前和化疗结束时的血常规检验指标的变化以及其与HLA-DRB1、DQB1多态性的关联，以期找到直肠癌化疗副损伤的相关的基因。方法选取78例直肠癌患者，采用多聚酶链反应-序列特异性引物(PCR-SSP)法检测其HLA-DRB1、DQB1的多态性。同时检测直肠癌患者化疗前和化疗结束时的血常规检验指标，包括：WBC、RBC、HGB、PLT、NEUT#、LYM#等。结果 HLA-DRB1*07有可能是化疗对RBC损伤的抵抗基因；HLA-DRB1*08有可能是化疗对LYM#损伤的敏感基因；HLA-DRB1*09有可能是化疗对RBC、HGB损伤的抵抗基因；HLA-DRB1*12有可能是化疗对RBC、HGB损伤的抵抗基因；HLA-DQB1*02有可能是化疗对RBC、HGB损伤的抵抗基因；HLA-DQB1*05有可能是化疗对HGB损伤的抵抗基因，同时HLA-DQB1*05也可能是化疗对NEUT#损伤的敏感基因；HLA-DQB1*07有可能是化疗对RBC、HGB损伤的抵抗基因。结论 HLA可能是肿瘤化疗副损伤的标志性基因。
Abstract
Objective To explore the related genes of Subsidiary-damage in tumor chemotherapy by the change of routine blood index of patients with rectal cancer before and after chemotherapy and their correlation with the polymorphism of HLA-DRB1/DQB1. Methods Total 78 patients with rectal cancer were selected. The DNA of every patient were extracted and the polymorphism of their HLA- DRB1, DQB1 was detected by PCR-SSP. Meanwhile, each index before and after chemotherapy were detected, including WBC、RBC、HGB、PLT、NEUT#、LYM# and so on. Results HLA-DRB1*07 may be resistance gene of RBC injury; HLA-DRB1*08 may be sensitive gene of LYM# injury; HLA-DRB1*09 may be resistance gene of RBC, HGB injury; HLA-DRB1*12 may be resistance gene of RBC、HGB injury; HLA-DQB1*02 may be resistance gene of RBC、HGB injury; HLA-DQB1*05 may be resistance gene of HGB injury and HLA-DQB1*05 may be sensitive gene of NEUT# injury; HLA-DQB1*07 may be resistance gene of RBC、HGB injury. Conclusion HLA may be marker genes of secondary impair of tumour chems.
关键词
HLA-DRB1/DQB1/直肠癌化疗/副损伤/检验指标Key words
HLA-DRB1/DQB1/Rectal cancer chemotherapy/Subsidiary-injury/Laborartory parameters引用本文复制引用
出版年
2013
NETL
NSTL
维普
万方数据